CNTB vs UPB
CNTB: Clinical-stage biopharmaceutical company developing rademikibart, an IL-4Rα-targeting monoclonal antibody to treat acute exacerbations of asthma and COPD. UPB: Upstream Bio is a clinical-stage biotech developing verekitug, a potentially best-in-class monoclonal antibody targeting the TSLP receptor for the treatment of severe respiratory inflammatory diseases.
Side-by-side fundamentals
| Metric | CNTB | UPB | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.20 | $6.59 | |
| Market cap as of 2026-07-23 | $139M | $376M | |
| Net margin as of 2026-07-23 | -21243.3% | -4719.0% | UPB higher |
| Operating margin as of 2026-07-23 | -21763.1% | -5176.5% | UPB higher |
| ROE as of 2026-07-23 | -122.3% | -43.8% | UPB higher |
| ROA as of 2026-07-23 | -97.1% | -42.3% | UPB higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +13.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +9.5% | |
| Beta as of 2026-07-23 | -0.23 | 1.77 | |
| 1-year return as of 2026-07-22 close | +10.5% | -34.4% | CNTB higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.